New and Revised Surviving Sepsis Campaign Recommendations with Bram Rochwerg

Value of the Information & Strength of the Argument

The value of the information is high for clinicians seeking an overview of the latest SSC recommendations. Rochwerg provides clear explanations of the methodology, which enhances understanding of the recommendations’ strength and applicability. The argumentation is solid, grounded in the GRADE framework and supported by references to key trials (e.g., the 65 trial). He also addresses potential criticisms, such as antimicrobial stewardship concerns, by highlighting the specific criteria for the prehospital antibiotic recommendation. The presentation is balanced, acknowledging limitations and the need for clinical judgment.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is evident in the detailed description of the guideline development process, including conflict of interest management, panel composition, and systematic evidence synthesis. The sources cited are primarily the guideline itself and key trials mentioned (e.g., the 65 trial). The title accurately reflects the content, which focuses on new and revised recommendations. The presentation is from an expert directly involved in the guideline, which adds credibility but also potential bias. No comments were provided for analysis.

The title accurately reflects the content, which focuses on new and revised recommendations from the Surviving Sepsis Campaign.

8/10

Presentation by a leading guideline methodologist and vice-chair of the Surviving Sepsis Campaign, with detailed description of rigorous GRADE methodology. However, it is a summary of recommendations without full evidence tables, and the speaker has a potential conflict as co-author.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of Bram Rochwerg and overview of the webinar.
• 05:00History and evolution of the Surviving Sepsis Campaign.
• 10:00Description of the guideline panel composition and international representation.
• 15:00Explanation of GRADE methodology and evidence-to-decision framework.
• 20:00Discussion of strong vs. conditional recommendations and good practice statements.
• 25:00Overview of the 129 recommendations and their distribution.
• 30:00New recommendation on prehospital sepsis screening.
• 35:00New recommendation on prehospital antibiotics for probable sepsis with hypotension.
• 40:00Revised MAP targets, including strong recommendation for MAP ≥65 and conditional for elderly.
• 45:00Discussion of empiric antibiotic choices and avoidance of anaerobic coverage in low-risk patients.

• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 — Referenced as the previous version of the guidelines, providing context for the updates.
• The 65 Trial — Mentioned as a key trial informing the MAP target recommendation for elderly patients.

• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 — The previous guidelines, which the 2026 update builds upon.

• Antimicrobial Stewardship Concerns — Some clinicians have expressed concerns about the prehospital antibiotic recommendation potentially contributing to antimicrobial resistance.